Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is cautiously positive: Cognition Therapeutics has a consensus “Moderate Buy” rating from four analysts, with three buys and one sell. The average 12-month price target is $3.33, substantially above the recent $1.06 share price.
• Institutional ownership has increased: Several investment firms recently added or initiated positions, and institutional investors now own 43.35% of the company’s stock.
• The company remains a clinical-stage biotech: Cognition is developing CT1812, an oral therapy targeting SIGMAR2 for Alzheimer’s disease and other dementias. Its latest quarterly loss of $0.04 per share was narrower than analysts’ expected $0.06 loss.

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the four brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $3.3333.

A number of equities analysts have recently commented on the company. Wall Street Zen downgraded Cognition Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. HC Wainwright restated a "buy" rating on shares of Cognition Therapeutics in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cognition Therapeutics in a research report on Wednesday, June 24th.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGTX. Northwestern Mutual Wealth Management Co. boosted its stake in Cognition Therapeutics by 11,695.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company's stock valued at $2,781,000 after buying an additional 2,042,815 shares in the last quarter. BlackRock Inc. acquired a new position in Cognition Therapeutics in the second quarter worth $1,451,000. Tocqueville Asset Management L.P. bought a new stake in shares of Cognition Therapeutics during the second quarter worth $369,000. Renaissance Technologies LLC raised its holdings in shares of Cognition Therapeutics by 15.2% in the first quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company's stock valued at $848,000 after buying an additional 147,623 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cognition Therapeutics in the second quarter worth about $165,000. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Stock Up 0.5%

NASDAQ CGTX traded up $0.01 during trading hours on Friday, hitting $1.06. 41,360 shares of the stock were exchanged, compared to its average volume of 1,075,277. The stock has a 50-day moving average of $1.00 and a 200 day moving average of $1.09. The company has a market cap of $101.28 million, a price-to-earnings ratio of -6.26 and a beta of 1.79. Cognition Therapeutics has a 12-month low of $0.55 and a 12-month high of $2.05.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. On average, equities research analysts expect that Cognition Therapeutics will post -0.3 earnings per share for the current year.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines for neurodegenerative diseases. The company's research centers on the sigma-2 receptor, also known as SIGMAR2, a protein believed to play a role in the cellular processes associated with cognitive decline and neurodegeneration.

Cognition Therapeutics' lead product candidate is CT1812, an orally administered, brain-penetrant small molecule designed to modulate SIGMAR2. The investigational therapy is being evaluated for Alzheimer's disease and other forms of dementia, including dementia with Lewy bodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.